Evidence map›Paper›PMID 38891433›Full record

ArticlePolymers2024

AlveoMPU: Bridging the Gap in Lung Model Interactions Using a Novel Alveolar Bilayer Film.

Minoru Hirano, Kosuke Iwata, Yuri Yamada, Yasuhiko Shinoda, Masateru Yamazaki, Sayaka Hino, Aya Ikeda, Akiko Shimizu, Shuhei Otsuka, Hiroyuki Nakagawa and 1 more

Abstract read
In one paragraph

Article in Polymers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Development of a sensor-compatible vascular microphysiological system for metabolic monitoring during drug-induced endothelial injury.Analytical sciences : the international journal of the Japan Society for Analytical Chemistry · 2025
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Minoru HiranoFrontier Research Management Office, Toyota Central R&D Labs., Inc., 41-1 Yokomichi, Nagakute 480-1192, Aichi, Japan.ORCID 0000-0002-4546-3864
Kosuke IwataOrganic Device Development Department, Material Development Division, Toyoda Gosei Co., Ltd., 1-1 Higashitakasuka, Futatsudera, Ama 490-1207, Aichi, Japan.ORCID 0009-0001-8377-9819
Yuri YamadaFrontier Research Management Office, Toyota Central R&D Labs., Inc., 41-1 Yokomichi, Nagakute 480-1192, Aichi, Japan.ORCID 0000-0001-8249-4283
Yasuhiko ShinodaOrganic Device Development Department, Material Development Division, Toyoda Gosei Co., Ltd., 1-1 Higashitakasuka, Futatsudera, Ama 490-1207, Aichi, Japan.
Masateru YamazakiOrganic Device Development Department, Material Development Division, Toyoda Gosei Co., Ltd., 1-1 Higashitakasuka, Futatsudera, Ama 490-1207, Aichi, Japan.
Sayaka HinoOrganic Device Development Department, Material Development Division, Toyoda Gosei Co., Ltd., 1-1 Higashitakasuka, Futatsudera, Ama 490-1207, Aichi, Japan.
Aya IkedaOrganic Device Development Department, Material Development Division, Toyoda Gosei Co., Ltd., 1-1 Higashitakasuka, Futatsudera, Ama 490-1207, Aichi, Japan.
Akiko ShimizuOrganic Device Development Department, Material Development Division, Toyoda Gosei Co., Ltd., 1-1 Higashitakasuka, Futatsudera, Ama 490-1207, Aichi, Japan.
Shuhei OtsukaOrganic Device Development Department, Material Development Division, Toyoda Gosei Co., Ltd., 1-1 Higashitakasuka, Futatsudera, Ama 490-1207, Aichi, Japan.
Hiroyuki NakagawaOrganic Device Development Department, Material Development Division, Toyoda Gosei Co., Ltd., 1-1 Higashitakasuka, Futatsudera, Ama 490-1207, Aichi, Japan.
Yoshihide WatanabeFrontier Research Management Office, Toyota Central R&D Labs., Inc., 41-1 Yokomichi, Nagakute 480-1192, Aichi, Japan.ORCID 0000-0001-9999-0486

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The alveoli, critical sites for gas exchange in the lungs, comprise alveolar epithelial cells and pulmonary capillary endothelial cells. Traditional experimental models rely on porous polyethylene terephthalate or polycarbonate membranes, which restrict direct cell-to-cell contact. To address this limitation, we developed AlveoMPU, a new foam-based mortar-like polyurethane-formed alveolar model that facilitates direct cell-cell interactions. AlveoMPU features a unique anisotropic mortar-shaped configuration with larger pores at the top and smaller pores at the bottom, allowing the alveolar epithelial cells to gradually extend toward the bottom. The underside of the film is remarkably thin, enabling seeded pulmonary microvascular endothelial cells to interact with alveolar epithelial cells. Using AlveoMPU, it is possible to construct a bilayer structure mimicking the alveoli, potentially serving as a model that accurately simulates the actual alveoli. This innovative model can be utilized as a drug-screening tool for measuring transepithelial electrical resistance, assessing substance permeability, observing cytokine secretion during inflammation, and evaluating drug efficacy and pharmacokinetics.

Indexed as

alveolardrug screeningin vitropolyurethaneporous membrane

Identifiers

PMID38891433
PMCPMC11174738

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.